# NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer

Source: https://onco.cc/trials/nct07178730/  
OnCo record `nct07178730` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of sacituzumab govitecan in triple-negative breast cancer, run by Women's Cancer Study Group GmbH, not yet recruiting.

## Summary

NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer. ClinicalTrials.gov record last updated 2026-08-05: not yet recruiting. Enrollment is planned at 765 participants. Primary completion is estimated at 2033-03-31. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Sacituzumab govitecan, Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA], SoC Chemotherapy. Registered primary measures: Cohort I: 3-year event-free survival (EFS); Cohort II: superiority of neoadjuvant treatment with SG+PEM vs. SoC with regards to event-free survival (EFS); Cohort II: superiority of neoadjuvant treatment with SG+PEM vs. SoC with regards to pathological complete response (pCR) rates.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-10-06
- Also known as: ADAPT-TN-IV
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07178730
- Phase: 3
- Setting: NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer
- Sponsor: Women's Cancer Study Group GmbH
- Enrolled: 765

## Notes

- ClinicalTrials.gov record last updated 2026-08-05: not yet recruiting. Enrollment is planned at 765 participants. Primary completion is estimated at 2033-03-31. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.

## Sources

- ClinicalTrials.gov NCT07178730: https://clinicaltrials.gov/study/NCT07178730

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [TROP2](https://onco.cc/targets/trop2/)
- drugs: [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07178730.json